Imugene Clarifies Scale-Back Terms on Securities Purchase Plan

Imugene ( (AU:IMU) ) just unveiled an announcement.

Imugene Limited has updated its Appendix 3B filing for a proposed issue of securities under a securities purchase plan, clarifying that any investor subscriptions may be scaled back at the company’s discretion. The clarification confirms that the scale-back provision applies to the offer, indicating Imugene’s intention to manage demand and capital raising size tightly, which may affect allocation outcomes for participating shareholders.

The update, lodged with the ASX on 19 March 2026 and amending an announcement made the same day, reinforces that the securities purchase plan remains in place but on terms that allow the company flexibility in controlling oversubscriptions. This approach provides Imugene with greater control over dilution and capital structure as it pursues funding for its operations and pipeline, while signalling to the market that investor interest could exceed the initial offer parameters.

The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.18 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is an ASX-listed biotechnology company focused on developing immuno-oncology therapies. The company operates in the biopharmaceutical sector, raising capital through equity markets to fund its research, development and clinical programs targeting cancer treatment.

Average Trading Volume: 1,507,511

Technical Sentiment Signal: Sell

Current Market Cap: A$57.87M

For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.